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Summary 
 
SHMT2 regulates one-carbon transfer reactions essential for amino acid and nucleotide 
metabolism, using PLP as a cofactor. Apo SHMT2 exists as a dimer with unknown 
functions, whereas PLP binding stabilizes the active, tetrameric state. SHMT2 also 
promotes inflammatory cytokine signaling by interacting with the BRISC deubiquitylase 
(DUB) complex, although it is unclear if this function relates to metabolism. We reveal the 
cryo-EM structure of human BRISC-SHMT2 complex at 3.8 Å resolution. The BRISC 
complex is a U-shaped dimer of four subunits and SHMT2 sterically blocks the BRCC36 
active site and inhibits DUB activity. Only the inactive SHMT2 dimer, but not the active, 
PLP-bound tetramer binds and inhibits BRISC. BRISC mutations that disrupt SHMT2 
binding impaired type I interferon signaling in response to inflammatory stimuli. 
Intracellular PLP levels regulated BRISC-SHMT2 interaction and inflammatory cytokine 
responses. These data reveal a new mechanism of metabolite regulation of DUB activity 
and inflammatory signaling. 
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Serine hydroxymethyltransferase 2 (SHMT2) functions in one-carbon folate metabolism 
supporting purine and thymine synthesis required for cell growth and proliferation. Full-
length SHMT2 localizes to mitochondria via an N-terminal mitochondria-targeting 
sequence (MTS), whilst an N-terminal truncation (residues 1-21) generates the 
cytoplasmic SHMT2a isoform 1,2 (Fig. 1a). Pyridoxal-5’-phosphate (PLP), the active form 
of vitamin B6, promotes a shift in SHMT2 oligomeric state from an inactive dimer to the 
enzymatically active tetramer 1,3. 
 
SHMT2 also controls inflammatory cytokine signaling via interaction with the 
deubiquitylating (DUB) enzyme BRISC (BRCC36 isopeptidase complex). BRCC36 is a 
JAMM/MPN+ Zn2+-dependent DUB and functions within two macromolecular complexes, 
requiring interaction with MPN– pseudo-DUBs Abraxas1 or Abraxas2 for DUB activity 4-6 
(Fig. 1a). The nuclear ARISC complex partners with RAP80 and BRCA1, forming the 
BRCA1-A complex required for DNA repair 7-9 10. Direct interaction with SHMT2 enhances 
BRISC delivery to ubiquitylated type I interferon (IFN) receptors (IFNAR1/2) 11,12 allowing 
BRCC36 to deubiquitylate K63-Ub chains on IFNAR1/2, limiting their endocytosis and 
lysosomal degradation 12. BRISC-deficient mice exhibit attenuated IFN responses and are 
protected from pathological conditions stemming from elevated inflammatory signaling 12. 
BRISC-SHMT2 association therefore provides a potential link between metabolism and 
inflammation. 
 
The BRCC36-Abraxas2 complex is an obligate dimer of heterodimers essential for DUB 
activity and IFN signaling 13,14. Similarly, BRISC and ARISC complexes are active as 
stable dimers of tetramers with stoichiometry 2:2:2:2 4,5,13,15. Structures of the human 
BRISC complex are unavailable and the molecular basis for SHMT2 binding and 
regulation is unknown. We present the cryo-EM structure of the BRISC-SHMT2 complex at 
3.8 Å resolution revealing the BRISC complex architecture and the molecular basis for 
DUB activity inhibition by SHMT2. Structure-guided mutations or increasing intracellular 
PLP levels reduced BRISC-SHMT2 interaction and inflammatory signalling, revealing a 
direct link between vitamin B6 metabolism and control of immune responses. 
SHMT2 is an endogenous BRISC inhibitor 
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We produced SHMT2DN (residues 18-504), which lacks the MTS and is a mixture of 
dimers and tetramers in solution (Fig. 1b). Tetramer peak fractions absorbed strongly at 
435 nm indicating PLP association, consistent with previous findings that PLP binding 
promotes a shift from an inactive dimer to the active SHMT2 tetramer 1 (Fig. 1c and 
Extended Data Fig. 1a, b). Dimer and tetramer peaks were confirmed by native mass 
spectrometry (MS) (Extended Data Fig. 1c).  
 
A serendipitous SHMT2 A285T mutation near the PLP acceptor Lys280 residue was 
identified by the Structural Genomics Consortium (PDBid 6DK3). SHMT2DN+A285T is 
dimeric in solution and crystal lattice, allowing a direct comparison between dimer (apo 
enzyme) and tetramer (holoenzyme) structures (Extended Data Fig. 1a-d). Individual 
SHMT2a-WT and SHMT2DN+A285T protomer structures are similar, suggesting that the 
A285T mutation does not significantly perturb the structure (Extended Data Fig. 1e). 
However, the A285T mutation reduces covalent PLP association, subsequent 
tetramerization and catalytic activity (Extended Data Fig. 2a, b). PLP addition induced 
SHMT2DN dimer-tetramer transition, leading to a large shift in thermal melting temperature 
(Extended Data Fig. 2c, d). This shift was largely reduced or abolished in A285T and 
K280A SHMT2 mutants, in agreement with studies showing SHMT2 mutations that 
abrogate PLP binding shift the equilibrium towards the dimer 1,16-19 (Extended Data Fig. 
2e).  
 
Addition of SHMT2DN inhibited BRISC DUB activity (Fig. 1d). Dimeric SHMT2DN was a 
better inhibitor (IC50 = 9 nM) than the tetrameric form (IC50 = 77.5 nM). As SHMT2DN 
tetramer is not fully saturated with PLP (Extended Data Fig. 2c, d), preincubation with 
PLP further reduced BRISC inhibition by the SHMT2DN tetramer (Fig. 1d). The obligate 
dimers SHMT2DN+A285T and SHMT2DN+K280A+A285T were effective inhibitors of 
BRISC and similar to SHMT2DN dimers (Fig. 1d). SHMT2DN+A285T DUB inhibition was 
selective for BRISC compared to ARISC (Fig. 1e), confirming that SHMT2 does not 
interact with the ARISC complex 12. These data suggest a previously unknown role for the 
dimeric (PLP-free) form of SHMT2 in regulating BRISC DUB activity.  
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BRISC-SHMT2 complex structure 
To understand the molecular basis of BRISC-SHMT2 association and how PLP-dependent 
SHMT2 oligomerization affects DUB activity, we solved the structure of the BRISC 
complex bound to an SHMT2 dimer. Using limited proteolysis we identified a minimal 
complex termed BRISCDNDC (Extended Data Fig. 3a, b), containing BRCC36, BRCC45, 
MERIT40DN (72-329) and Abraxas2DC (1-267). BRISC and BRISCDNDC were active 
towards a fluorogenic K63-linked diUb substrate (Extended Data Fig. 3c), and were each 
inhibited by SHMT2DN+A285T with similar IC50 values (Extended Data Fig. 3d). 
SHMT2DN+A285T formed a stable, equimolar complex with BRISCDNDC (Extended Data 
Fig. 3e, f).  
 
We used negative stain electron microscopy (EM) and single particle cryo-EM to evaluate 
BRISCDNDC and BRISCDNDC-SHMT2DN+A285T complexes. BRISCDNDC particles 
showed distinct U-shaped assemblies similar to those seen for the nuclear ARISC 
complex 15. However, BRISCDNDC showed heterogeneity and flexibility of the “arm” 
regions (Extended Data Fig. 4a). The BRISCDNDC-SHMT2DN+A285T complex was 
homogeneous, with SHMT2DN+A285T bridging both arms of the U-shaped BRISC 
structure in 2D class averages (Extended Data Fig. 4a). We collected a large cryo-EM 
dataset, and identified ~11% (71,262 particles) with a structure with apparent C2 
symmetry, containing a central trapezoid region and two extending arms. The remaining 
particles are missing one arm (Extended Data Fig. 4b, c). After 3D classification and 
refinement, using both C1 and C2 symmetry, we obtained EM density maps at 3.8 Å and 
4.2 Å resolution respectively (Extended Data Fig. 4c, d; Extended Data Table 1).  
 
BRISCDNDC complex comprises a central core region and two extending arms. Insect 
BRCC36-Abraxas2 structure (PDBid 5CW3) 13 was fitted at the base of the map, and the 
quality of the EM density in this region was sufficient for modeling the human BRCC36-
Abraxas2 sequence into the structure (Fig. 2). The SHMT2DN+A285T dimer was 
immediately recognizable in the EM map, with the structure (PDBid 6DK3) fitting directly 
above the BRCC36-Abraxas2 MPN domains (Fig. 2). The remaining unoccupied density 
belongs to BRCC45 and MERIT40, for which no experimental structures are available.  
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BRCC45 contains two UEV domains at its N- and C-termini. We used the FFAS03 20 and 
HHpred 21 algorithms to search for additional domains and identified a putative “UBC-like” 
domain within residues 144-280, suggesting the presence of a middle UEV domain (UEV-
M). Tandemly repeated domains are common during protein evolution, reinforcing the 
independent prediction of a third UEV domain in BRCC45 (Fig. 1a) 22. Consistent with this 
hypothesis, we manually built a Ca-backbone structure for two consecutive UEV domains 
of BRCC45 into the density immediately extending from Abraxas2 (Fig. 2a). However, due 
to the low resolution of this region, precise assignment of the sequence was not possible.  
 
We used the related ARISC complex structure 15 as a guide to place homology models of 
MERIT40 and a third UEV (BRCC45) domain within the “fist”-like density in the distal 
region of each arm (Fig. 2a). The resolution in this peripheral region is poor (~10 Å), so it 
was not possible to ascertain the precise orientation of the vWFA (MERIT40) and UEV-C 
(BRCC45) domains. We modelled UEV-N and UEV-C in proximity of Abraxas2 and 
MERIT40 (respectively), in accordance with previous deletion studies 4,23 (Fig. 2a). Thus, 
a complete BRISC-SHMT2 model was built using a combination of known structures, de 
novo model building and homology modeling (Fig. 2a). The “core” structure consisting of 
the BRCC36-Abraxas2 superdimer and the SHMT2 obligate dimer are well resolved with 
local resolution of 3.5-4.0 Å (Extended Data Fig. 4c, d and 5a, b).  
  
SHMT2 bridges the two arms of the BRISC complex and sits directly above the BRCC36-
Abraxas2 superdimer, explaining the requirement for superdimer formation in SHMT2 
binding 13. SHMT2 interacts with MPN domains of BRCC36 and Abraxas2 and UEV-N and 
UEV-M of BRCC45 (Fig. 2a). The main BRISC-interacting surface on SHMT2 is centered 
on the two a6 helices, and proximal residues between SHMT2-Abraxas2, SHMT2-
BRCC36 and Abraxas2-BRCC45 are shown in Fig. 2b. MERIT40 does not contact 
SHMT2 directly (Fig. 2a) and its position may provide stabilizing interactions to BRCC45, 
while also interacting with other signaling molecules 24. Comparison between human and 
insect BRCC36-Abraxas2 superdimers reveals a similar overall structure, with minor local 
shifts (Extended Data Fig. 5c-e). Overall, the structure provides the first view of the 
interaction surfaces between SHMT2 and components of the BRISC complex. 
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Prior work suggested that BRISC also interacts with SHMT1 in cells, although cellular 
BRISC-SHMT2 complexes were much more abundant 12. To test if SHMT2 and SHMT1 
interact equally with BRISC in vitro, we purified SHMT1 dimers and tetramers, but failed to 
assemble BRISC-SHMT1 complexes, and observed no inhibition of BRISC DUB activity in 
vitro (Extended Data Fig. 6). While it remains possible that BRISC-SHMT1 complexes 
form in cells, we predict these will be lower affinity in comparison with BRISC-SHMT2 
complexes and may be a consequence of indirect interactions with other factors. 
 
We mutated SHMT2 residues in proximity to BRISC (Fig. 2b) and assessed their effects 
on DUB activity in vitro. Mutations were made in the SHMT2DN+A285T background, which 
purifies as a dimer (Extended Data Fig. 7a, b). SHMT2DN+A285T containing L211R or 
L215R were each less potent inhibitors of BRISC DUB activity when compared to 
SHMT2DN+A285T, while the L211R+L215R mutant had no detectable inhibitory effect on 
BRISC activity (Extended Data Fig. 7c). SHMT2DN inhibition was also observed with 
hexaUb chains as substrates (Extended Data Fig. 7d). DUB activity was only marginally 
reduced when assayed with SHMT2DN+A285T+L211R+L215R, SHMT2DN tetramers or 
SHMT1, mirroring results obtained with fluorescently labeled diUb, and consistent with the 
observation that L211R+L215R mutations reduce BRISC-SHMT2 interaction in vitro 
(Extended Data Fig. 8a). These experiments establish SHMT2 helix a6 as the most 
important contact surface for BRISC interaction and DUB activity inhibition.  
 
BRISC-SHMT2 impacts immune signaling 
To understand the relevance of the BRISC-SHMT2 interaction in cells, we mutated 
interface residues between SHMT2, Abraxas2 and BRCC45 (Fig. 2b) and assessed 
interactions by co-immunoprecipitation (Fig. 3a, b). Consistent with the loss of interaction 
with SHMT2, Abraxas2 mutants A142R, E144A and E144R expressed in Abraxas2–/– 
MEFs showed reduced STAT1 phosphorylation in response to HSV infection, as did 
N100R, Y107R and D23R mutants, which either reduce or prevent BRCC45-MERIT40 
binding (Fig. 3c). The BRISC-SHMT2 interaction was also required for immune signaling 
when cells were challenged using LPS or IFNb (Fig. 3d). Moreover, we observed 
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increased IFNAR1 ubiquitylation after IFN stimulation of cells overexpressing the Abraxas2 
E144R mutant (Extended Data Fig. 7e).  
 
For a broader view of immune signaling output dependent on the BRISC-SHMT2 complex, 
we performed qRT-PCR analysis of 79 genes commonly upregulated during a type I 
interferon response. Ectopic expression of WT-Abraxas2 resulted in 48 genes upregulated 
between 2-8,000 fold in response to LPS (Fig. 3e and Extended Data 9a). Accordingly, 
LPS challenging of Abraxas2–/– (KO) cells or KO + Abraxas2 E144R cells showed a poor 
response, with 11 and 8 genes (respectively) upregulated 2-10 fold compared to non-
challenged KO cells (Fig. 3e).  
 
We next mutated SHMT2 residues to ascertain their importance in cellular assembly of 
BRISC-SHMT2 complexes. Overexpression of SHMT2DN+L211R+L215R  resulted in loss 
of BRISC-SHMT2 interaction in MEF cells, mirroring the results seen in vitro (Extended 
Data Fig. 7f and 8a). pSTAT1 levels were also affected in cells challenged with 
LPS (Extended Data Fig. 7g), and we observed increased IFNAR1 ubiquitylation after 
IFN stimulation of cells overexpressing the SHMT2DN+L211R+L215R mutant (Extended 
Data Fig. 7e). Collectively, these findings reveal the specific Abraxas2 and SHMT2 
surfaces that are required for BRISC-SHMT2 complex assembly and immune signaling in 
cells. 
 
The positioning of SHMT2 within the structure provides a potential rationale for its 
inhibition of DUB activity since it blocks the BRCC36 active site (Extended Data Fig. 8b). 
Kinetic data suggests SHMT2 acts as an apparent competitive inhibitor (Extended Data 
Fig. 8c). However, the increase in Km was only moderate (~2-fold at equimolar BRISC-
SHMT2 complex), suggesting that K63-Ub chains might displace bound SHMT2 from 
BRISC when poly-ubiquitylated substrates are in close proximity. This model would 
account for the counterintuitive function of SHMT2 as both an inhibitor of BRISC activity 
and an essential mediator of BRISC association with sites of DUB action (Extended Data 
Fig. 10). It is also possible that other factors and post-translational modifications trigger 
SHMT2 dissociation from BRISC in cells. We propose that SHMT2 acts as a reversible 
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endogenous BRISC inhibitor that prevents non-specific DUB activity. This regulated safety 
mechanism is similar in concept to protease inhibition by endogenous inhibitors 25. To our 
knowledge, SHMT2 is the first example of an endogenous DUB inhibitor, acting as a 
precedent for the possible regulation of other DUBs in vivo.  
 
Regulation of BRISC-SHMT2 interaction by PLP 
BRISC DUB inhibition provides the first non-enzymatic role of the SHMT2 dimer. Our 
structure explains why the apo SHMT2 dimer, but not the PLP-bound tetramer inhibits 
DUB activity. SHMT2 helix a6 interacts with BRISC which overlaps with the SHMT2 
tetramerization surface, accounting for the observation that SHMT2 tetramer and the 
BRISC-SHMT2 complexes are mutually exclusive (Extended Data Fig. 1b and 8d). The 
SHMT2DN-PLP tetramer does not form BRISC-SHMT2 complexes in vitro (Extended 
Data Fig. 8e), suggesting that PLP-induced tetramerization could regulate SHMT2 dimer 
availability, and BRISC-SHMT2 complex formation in cells.  
 
To test this hypothesis, we cultured MEF and 293T cells in B6 vitamer-free media and 
compared the BRISC-SHMT2 interaction after pyridoxal (PL) supplementation (Fig. 4a). 
PLP levels were confirmed by vitamin B6 metabolite measurements in whole cell lysates 
(Fig. 4b), and fewer SHMT2 dimers are present after PL supplementation (Extended Data 
Fig. 9b). This coincided with a marked reduction of overexpressed SHMT2DN and 
endogenous Abraxas2 interaction (Fig. 4a). Similarly, the interaction between 
overexpressed Abraxas2 and endogenous SHMT2 was reduced (Fig. 4c). The PLP-
dependent reduction of BRISC-SHMT2 interaction was not observed when PLP-resistant 
SHMT2 mutants were expressed (Fig. 4d).  
 
We next measured pSTAT1 levels and observed a PL-dependent reduction of pSTAT1 
upon IFNb stimulation (Fig. 4e and Extended Data Fig. 9c). This reduction was not 
observed when PLP-resistant SHMT2 mutants were expressed (Fig. 4e, Extended Data 
Fig.  9d). Consistently, we observed an increase in both BRISC-SHMT2 complexes (Fig. 
4d and Extended Data 9e) and pSTAT1 levels when PLP-resistant SHMT2 mutants were 
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expressed in cells cultured in B6 vitamer-containing media and challenged with IFNb or 
HSV (Fig. 4e, Extended Data Fig. 9d, f). Finally, we observed a PL-dependent reduction 
of nine IFN-induced genes in LPS-challenged MEFs that stably express SHMT2DN, but 
saw no change in MEFs where a PLP-resistant mutant was expressed (Fig. 4f). 
Interestingly, IL10 was upregulated by 2.1-fold in PL+ SHMT2DN cells (Fig. 4f), although 
this was not upregulated in LPS-stimulated Abraxas2 cells, suggesting that IL10 is not 
directly dependent on BRISC-SHMT2 (Extended Data 9a). These experiments provide 
further evidence that PLP binding to SHMT2 regulates BRISC-SHMT2 interaction and 
immune signaling in cells. 
 
Endogenous small molecule ligands that control ubiquitin signaling could be 
physiologically important. PLP influence on BRISC activity establishes a regulatory 
precedent for DUBs, akin to the plant hormone auxin and the second messenger inositol 
hexakisphosphate, which both allosterically regulate the activity of E3 ubiquitin ligases 26. 
Post-translational modifications of the PLP acceptor lysine 27,28 could provide additional 
layers of regulation for BRISC-SHMT2 association and immune signaling. It is possible 
that natural and synthetic SHMT2 binders, such as folate and PLP analogues, can 
modulate dimeric SHMT2 availability or conformation and thus interferon signaling 
(Extended Data Fig. 10). Understanding the regulatory mechanisms of BRISC-SHMT2 
interactions will therefore be useful to unlock the potential for such molecules as 
therapeutics.   
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Data availability 
Coordinates were deposited in the Protein Data Bank: PDBid 6R8F. Cryo-EM 
reconstructions in C1 and C2 were deposited in the EM Data Bank: EMD-4759 and EMD-
4760. 
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Materials and Methods 
Cloning, protein expression and purification of BRISC-SHMT2 complex and SHMT1 
Genes for the four-subunit human BRISC complex were cloned in the MultiBac system 
used for co-expression of multiprotein complexes in insect cells (Sf9) 29. A single 6-His 
purification tag followed by a cleavable TEV site was engineered at the N-terminus of 
BRCC45. Virus preparation, protein production and protein purification were performed as 
previously described by Zeqiraj et al., 2015 13. 
 
Wild-type and mutant forms of human SHMT2DN (residues 18-504) and SHMT1 were 
cloned in a pProEx-HTb vector and expressed in E. coli BL21 (DE3) codon plus RIL in 
Terrific Broth (TB) in the presence of 100 μg/ml Ampicillin and 34 μg/ml Chloramphenicol 
at 37 oC to an OD600 of 1.0-1.2 AU. Cells were then induced with 0.5 mM isopropyl-1-thio-
D-galactopyranoside (IPTG) and incubated overnight at 18 oC. Cells were harvested by 
centrifugation at 5,500g and cell pellets were resuspended in lysis buffer (50 mM Tris-HCl, 
pH 7.6, 300 mM NaCl, 20 mM imidazole, 0.075% b-mercaptoethanol, 5% glycerol, 1 mM 
Benzamidine, 0.8 mM phenylmethyl sulfonyl fluoride (PMSF) and 0.3 mg/ml lysozyme). 
Cells were lysed by sonication (1 sec on, 3 sec off for a total of 16 min) on ice and the 
lysates were cleared by centrifugation at 26,000g. The clarified lysate was loaded onto a 5 
ml chelating FastFlow column (GE Healthcare), charged with Ni2+. The column was 
washed with 4 column volumes (CV) of wash buffer consisting of 50 mM Tris-HCl (pH 7.6), 
500 mM NaCl, 20 mM imidazole, 0.075% b-mercaptoethanol and 1 mM Benzamidine, and 
the protein was eluted by applying an imidazole gradient with elution buffer consisting of 
50 mM Tris-HCl (pH 7.6), 300 mM NaCl, 300 mM imidazole, 0.075% b-mercaptoethanol 
and 1 mM Benzamidine. The fractions containing SHMT2DN or SHMT1 were pooled and 
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dialyzed against buffer containing 20 mM MES, pH 6.5, 250 mM NaCl, 5% glycerol, 20 mM 
imidazole, 0.075% b-mercaptoethanol and 1 mM Benzamidine. TEV was added to the 
protein sample and incubated overnight at 4 oC. Dialyzed protein was loaded on a 16/600 
Superdex200 column (GE Healthcare), equilibrated with 20 mM MES (pH 6.5), 500 mM 
NaCl and 2 mM TECP.  
 
BRISCDNDC and SHMT2DN+A285T were mixed in vitro at 1:4 molar ratio and incubated 
on ice for 40 min. The mixture was then injected onto a Superdex 10/300 S200 column 
and peak fractions were analysed by SDS-PAGE. Fractions containing the BRISCDNDC-
SHMT2DN+A285T complex were pooled and BRISC-SHMT2DN+A285T complex was 
used immediately for grid preparation and EM analysis as described below. The remainder 
BRISC-SHMT2DN+A285T complex was pooled and stored at -80 oC at a final 
concentration of 0.5 mg/ml. Denatured and native masses of all protein preparations were 
verified by mass spectrometry.  
 
Negative stain EM 
BRISCDNDC and BRISCDNDC-SHMT2DN+A285T complexes were diluted in buffer (25 
mM Hepes, pH 7.5, 150 mM NaCl, 1 mM TCEP) to 0.0041 mg/ml and 0.0051 mg/ml 
respectively, immediately prior to grid preparation. Glow-discharged, 300-mesh carbon-
coated copper grids (Agar scientific) were incubated with 7 µl BRISCDNDC or 
BRISCDNDC-SHMT2DN+A285T for 60 sec, passed through 3 droplets of water and 
stained twice with 2% w/v uranyl acetate for 20 sec and 10 sec respectively. Excess liquid 
was removed by blotting. Micrographs were collected on an FEI Tecnai F20 electron 
microscope operated at 120 kV equipped with an FEI Ceta CMOS camera. Data 
processing was carried out using RELION 2.1. Initially, ~1,500 particles were picked 
manually and extracted with a 450 Å2 box size. Particles were subjected to reference-free 
2D classification to generate initial references for auto-picking. A total of 28,566 and 
26,824 particles were picked for the BRISCNDC and BRISCDNDC-SHMT2DN+A285T 
complexes respectively. One round of reference-free 2D classification was then carried out 
for each.  
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Cryo-grid preparation and data collection 
BRISCDNDC-SHMT2DN+A285T complex was diluted to 0.05 mg/ml in buffer (25 mM 
Hepes, pH 7.5, 150 mM NaCl, 1 mM TCEP) immediately prior to grid preparation. Cryo-
EM grids were prepared by placing 3 µl of this complex onto glow-discharged, 200-mesh 
copper grids (Quantifoil R1.2/1.3), followed by immediate blotting and plunge-freezing in 
liquid ethane cooled by liquid nitrogen, using an FEI Vitrobot IV at 95 % relative humidity, 
chamber temperature of 4 oC. Datasets were collected on an FEI Titan Krios transmission 
electron microscope at 300 kV, using a total electron dose between 83-95 e-/Å2, a 
magnification of 75,000x and a final calibrated object sampling of 1.065 Å/pixel. Three 
independent datasets giving a total of 7,494 movies were recorded using the EPU 
automated acquisition software on an FEI Falcon III direct electron detector 30. Each 
exposure movie had a total exposure time of 2 sec collected over 70-79 frames with an 
electron dose of 1.2 e-/A2 per frame. Detailed information on data collection is shown in 
Extended Data Table 1.  
 
Image processing 
A schematic of the data processing pipeline is shown in Extended Data Fig. 4. Image 
processing was carried out using RELION 3.0 31. Drift-corrected averages of each movie 
were created using MOTIONCORR2 32 and the contrast transfer function of each 
determined using gCTF 33. Initially, ~ 2,000 particles for each dataset were manually 
picked, extracted with a box size of 373 Å2 and subjected to reference-free 2D 
classification to generate initial references for auto-picking. After auto-picking, each 
dataset was individually subjected to iterative rounds of reference-free 2D classification. 
Based on visual inspection, quality 2D average classes were selected for each dataset 
and then the three sets were combined. An initial model generated ab initio from the 2D 
class averages of the BRISCDNDC-SHMT2 negative stain data, filtered to ~60 Å, was 
used for initial 3D classification of the combined dataset. Of the eight classes generated, 
one contained particles comprising the intact complex, i.e. the BRCC36-Abraxas2-SHMT2 
core and both BRCC45-MERIT40 arms. This class was processed as a separate dataset 
consisting of 71,262 particles, representing the complete, 2-arm structure. In parallel, this 
class along with four others, totalling 514,930 particles, was processed to represent the 
complete dataset. Both were subjected to a final round of 3D classification to remove any 
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remaining ‘bad’ particles. The best classes from 3D classification were taken forward and 
subjected to 3D refinement, per-particle CTF correction and particle polishing 31. C2 
symmetry was imposed to the 2-arm dataset. Post-processing was used to appropriately 
mask the model, estimate and correct for the B-factor of the maps. Final resolutions were 
determined using the ‘gold standard’ Fourier shell correlation criterion (FSC = 0.143). 
Local resolution was estimated using the local resolution feature in RELION.  
 
Model building and refinement 
A preliminary model for the BRISCDNDC-SHMT2DN+A285T complex was generated using 
a combination of known crystal structures [BRCC36-Abraxas2 superdimer from 
Camponotus floridanus (PDBid 5CW3) and human SHMT2 dimer (PDBid 6DK3)] and 
homology models generated by Phyre2 34 (BRCC45, consisting of two UEV domains, and 
MERIT40). This initial model was manually fitted into the EM density map for the C1 
reconstruction (3.8 Å) using rigid body fitting in UCSF Chimera 35. The model was then 
manually fitted and rebuilt in COOT 36 to trace the human sequences of BRCC36 and 
Abraxas2. Amino acid residues which lacked unambiguous density were deleted or 
modelled up to their Cb position while preserving sequence information. The Ca-backbone 
for BRCC45 UEV-N and -M was traced into the remaining density mainly as alanine and 
glycine residues and the precise sequence for BRCC45 could not be modelled with 
confidence. Gaps numbered arbitrarily were left where direct connectivity between 
secondary structure elements could not be determined.  
The higher resolution C1 map was used for initial model building and the 2-arm model was 
generated by using the two-fold symmetry of the superdimer core.  
The model was refined against the C1 and C2 maps in Phenix 37 using default parameters 
and secondary structure restraints. The overall quality of the model was assessed using 
MolProbity 38. Fitting of the remaining BRCC45 UEV-C and MERIT40 domains into the 
peripheral parts of the C2 EM map was carried out using rigid body fitting in Chimera and 
these are displayed for relative position and size comparison purposes only.  
 
DUB activity assays  
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BRISC complexes were assayed at 30 oC in DUB reaction buffer containing 50 mM 
HEPES-NaOH pH 7.0, 100 mM NaCl, 0.1 mg/ml BSA, 1 mM DTT and 0.005% Tween-20. 
Internally quenched fluorescent (IQF) K63-linked diUb (Lifesensors, catalog number: 
DU6303) was used as a reporter for DUB activity [1 part IQF diUB : 9 parts unlabelled 
K63-linked diUb prepared as described by Pickart and Raasi 2005 39]. 20-μl enzyme 
reactions were carried out in 384-well black flat-bottom low flange plates (Corning; 35373). 
Cleaved diUb was monitored by measuring fluorescence intensity (Ex 540 nm, Em. 580 
nm; dichroic mirror 560 nm) every 1 min over 20 min, and initial velocity (vo) was 
calculated as the slope of the linear part of the reaction progress curve. Fluorescence 
intensity units were converted to nM product concentration using TAMRA-labelled ubiquitin 
(Lifesensors, catalog number: SI270T) as a standard. Enzyme concentrations for which a 
reasonable progress curve was obtained over 20 min were: 1 nM BRISC and 40 nM 
ARISC. Substrate concentration was 300 nM. IC50 values were calculated by fitting the 
data using the GraphPad Prism built-in dose-response equation for inhibition with variable 
slope: Y = Bottom+(Top—Bottom)/(1+10((LogIC50—X)*h)). Michaelis-Menten analysis in the 
absence and presence of increasing concentrations of SHMT2 were performed in DUB 
buffer containing 50 mM HEPES-NaOH (pH 6.8), 100 mM NaCl and 5 mM DTT. BRISC 
concentration was 1.5-2.0 nM and IQF K63-linked diUb was used (0-4 μM) as substrate 
(concentrations greater than 4 μM inhibited BRISC activity). Data were fit using the 
standard Michaelis-Menten equation, constraining Vmax to be less than the Vmax in the 
absence of SHMT2. Lineweaver-Burk plots and Michaelis-Menten analysis were 
performed using GraphPad Prism. 
 
K63-linked hexaUb chains were also used to determine DUB activity. 60 µl reactions were 
carried out in 1.5 ml Eppendorfs at 30 °C in DUB reaction buffer. BRISC was incubated in 
the presence or absence of SHMT2DN or SHMT1 forms for 30 mins at room temperature 
prior to K63-Ub6 addition. Reactions containing 0.5 nM BRISC, 2 µM SHMT, 1 µM K63-
Ub6 were incubated for 1 hour. Immunoblotting was performed with commercially available 
HRP-conjugated antibody to Ub  (P4D1, Santa Cruz). 
SHMT2 PLP association and enzyme activity assays 
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PLP association assays were performed in 20 µl reactions in 384-well plates (Greiner) in 
buffer containing 50 mM HEPES-Na (pH 7.8), 50 mM NaCl, 50 mM KCl, 5% glycerol, 0.2 
mM DTT, 0.1 mM EDTA and 0.005% Tween-20. SHMT2DN and point mutants (5 µM) 
were rapidly mixed with PLP (100 uM) and the reaction was monitored by measuring 
absorbance at 435 nm (every 30 sec over 1 hour) using a Hidex Sense microplate reader.   
SHMT2DN enzyme activity was monitored in 20 µl reactions in 384-well, UV-transparent 
plates (Greiner). The synthetic substrate L-threo-phenylserine (2S,3R)-2-amino-3-hydroxy-
3-phenylpropionic acid (BACHEM) was used as described previously 40 with minor 
modifications. Reactions were performed in buffer containing 50 mM HEPES-Na (pH 7.5), 
100 mM NaCl, 0.5 mM TCEP and 0.005% Tween-20. SHMT2DN and point mutants (2 µM) 
were preincubated with 200 µM PLP for 1 hour at 25 oC. 5 µl of enzyme-PLP solution was 
added to 15 µl of solution containing 0-260 mM L-threo-phenylserine and the reaction was 
monitored by measuring absorbance of benzyldehyde at 279 nm in a Hidex Sense 
microplate reader (every 2 min over 20 min). Absorbance units were converted to molar 
concentrations using a standard curve of known concentrations of benzyldehyde solutions 
(Sigma). Initial velocity (vo) was calculated as the slope of the linear part of the reaction 
progress curve (20 min). 
 
Differential scanning fluorimetry (DSF) 
Thermal-shift assays were performed using an Applied Biosystems StepOnePlus Real-
Time PCR instrument and a standardized DSF procedure 41. Proteins were diluted in 50 
mM Tris-HCl (pH 7.4) and 100 mM NaCl to a concentration of 5 μM and then incubated 
with the indicated concentration of compound in a total reaction volume of 10 μL, with final 
concentration of 2% (v/v) DMSO. SYPRO Orange (Invitrogen) was used as a 
fluoresecence probe. The temperature was raised in regular 0.3 °C intervals from 25 °C to 
95 °C. Compound binding experiments were assessed in duplicate and reported relative to 
DMSO controls. Normalized data were processed using the Boltzmann equation to 
generate sigmoidal denaturation curves, and  Tm/ΔTm values were calculated as previously 
described 41. 
 
Native mass spectrometry (MS) 
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BRISCDNDC-SHMT2DN+A285T (2.6 µM) and SHMT2DN and various mutants (2-20 µM) 
were buffer exchanged into 0.2-1 M ammonium acetate (pH 7.2) using Zeba Spin 7K 
MWCO desalting columns (ThermoFisher). Samples were analysed by nanoelectrospray 
ionisation MS using either a quadrupole-IMS-orthogonal time-of-flight (TOF) MS (Synapt 
HDMS, Waters UK Ltd., Machester, UK), operated as described previously 42 or a 
quadrupole orbitrap MS modified for transmission of high m/z ions (Q-Exactive Plus, 
ThermoScientific), operated as described previously 43,44. Both used gold/palladium coated 
nanospray tips prepared in-house. Data from the Synapt was processed using the 
MassLynx v4.1 suite of software supplied with the mass spectrometer and UniDec v2.7.1 
45. Data from the Q-Exactive Plus was processed using Xcalibur Qual Browser v4.0.27.19 
and UniDec v2.7.1.  
Analytical size exclusion chromatography  
BRISC-FL and SHMT2DN or SHMT1 forms were mixed in vitro at 1:1 molar ratio (~6 µM) 
and incubated on ice for 30 min. The mixture was then injected onto a 2.4 ml Superose 6 
analytical size exclusion column.  Peak fractions were analysed by SDS-PAGE. Controls 
for each protein were also run. 
 
Immunoprecipitation and immunoblots 
All immunoprecipitations were performed as previously described 46. Briefly, BRCC36 and 
Abraxas2 expressing cells were lysed in NETN 150 (0.5% NP40, 25 mM Tris pH 7.5, 150 
mM NaCl, 0.5 mM EDTA with 1mM PMSF). Flag-IPs were performed on lysate 
supernatants for 4 hours with agarose conjugated anti-Flag M2 beads (Sigma) prior to 
elution in 0.1 mM glycine (pH 2.5). Immunoblots were performed with the following rabbit 
polyclonal antibodies at 1:1000 dilution that were generated to recombinant proteins: 
MERIT40, Abraxas2, BRCC36 and BRCC45. Commercially available antibodies to HA 
epitope (HA.11 Covance) and SHMT2 (Cell Signaling) were used according to the 
manufacturer’s directions. An Abraxas2 deletion mutant (DM1) was used as control as 
described previously 12. 
 
For assessment of IFNAR1 ubiquitylation in cells, cells were lysed in buffer containing 2% 
SDS, 150 mM NaCl, 10 mM Tris-HCl, pH 8.0, 50 mM sodium fluoride, 10mM N-
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Ethylmaleimide and protease inhibitors. After boiling for 10 mins, cell lysates were further 
diluted in immunoprecipiation buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM EDTA, 
1% Triton). IFNAR1 were immunoprecipitated with a corresponding antibody (Bethyl 
Laboratories A304-290A). Resulting samples were separated by SDS-PAGE and analyzed 
by immunoblotting using the anti-ubiquitin antibody (Lifesensor, VU101).  
Response to HSV infection, LPS, and IFN-b  
HSV lacking the ICP0 gene was used to infect cells at a multiplicity of infection of 0.1 for 2 
hours. Media was then changed followed by a 5-hour incubation period. Cells were then 
lysed in NETN150 and lysates were run on a 4-12% gradient SDS-PAGE gel for 
immunoblot. Phospho-STAT1 and STAT1 antibodies were purchased from Cell Signaling 
Corporation and used according to the manufacturer’s specifications. Monitoring of 
phospho-STAT1 after LPS or IFN-b treatment was performed using similar conditions as 
described previously 12. 
 
Cellular PLP level manipulation and validation  
MEF or 293T cells were cultured in B6 vitamer-free Dulbecco’s modified eagle’s medium 
(DMEM, from Gibco), B6 vitamer-free DMEM + 20 μmol/L pyridoxal hydrochloride (PL, 
from Sigma) or B6 vitamer-free DMEM+ 50 μmol/L PL. All media were supplemented with 
10% FBS. After 48 hours culture, cells were collected and snap frozen in liquid nitrogen. 
Pyridoxal, pyridoxal phosphate, and pyridoxine levels was measured using LC/MS as 
described previously 47. 
 
qRT-PCR analysis of gene expression in MEFs 
IFN type I-related gene expression was analysed in Abraxas2–/– MEFs following treatment 
with either LPS or vehicle control. Gene expression was performed in Abraxas2-/- MEFs 
and compared to derivative lines that had been stably reconstituted with Abraxas2 WT or 
mutant E144R using retroviral transduction. Following 16 hours of LPS exposure, cells 
were directly lysed in TRIzol™ (Thermo Fisher Scientific, Waltham, MA) and RNA 
extracted using Quick-RNA Miniprep Kit (Zymo Research, Irvine, CA) as per 
manufacturer’s instructions. 400 ng of eluted RNA was converted to cDNA using RT2 First 
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Strand Kit (Qiagen). Next, the cDNA was mixed with RT2 SYBR Green Mastermix 
(Qiagen, Venlo, Netherlands). The mouse IFN I RT2 Profiler PCR Array (Qiagen cat. no. 
PAMM-016Z) was performed and relative expression determined using the ∆∆CT method 
and normalized for 4 housekeeping genes according to manufacturer’s guidance. Single 
measurements of three biological repeats were performed. Total results were analysed 
and compared to Abraxas2–/– MEFs gene signature, with and without LPS treatment. Gene 
expression analysis of MEFs cultured in vitamer-free B6 with and without 20 µM PL was 
performed as above.  
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Figure Legends 
 
Figure 1. SHMT2 dimer inhibits BRISC DUB activity 
a) Domain architecture of SHMT2 and BRCC36-containing complexes. MTS = mitochondria-targeting 
sequence, SHMT = serine hydroxymethyltransferase, MPN = Mpr1/Pad1 N-terminal, CC = coiled coil, UEV = 
Ubiquitin E2 variant, vWFA = von Willebrand factor type A.   
b) SHMT2DN elution profile after size exclusion chromatography, monitored by measuring A280. SHMT2DN 
bound to pyridoxal-5’-phosphate (PLP) was detected by measuring A435. Data are representative of three 
independent experiments.   
c) Schematic of SHMT2DN dimer-tetramer equilibrium in response to PLP binding.   
d) BRISC DUB activity against a fluorogenic K63-linked diUb substrate in the presence of SHMT2DN forms.  
e) BRISC and ARISC DUB activity against a fluorogenic K63-linked diUb substrate in the presence of 
SHMT2DN+A285T. Data in d, e are average +/– SEM of three independent experiments carried out in 
duplicate.   
 
 
Figure 2. Structure of the BRISC-SHMT2 complex 
a) Cryo-EM density at contour level of 0.055 (C2 map) shown in transparent surface. Proteins are 
depicted as cartoon models. Due to low resolution in the extended “arm” regions, UEV-C 
(BRCC45) and vWFA (MERIT40) models are shown for size comparison only. b) Close-up view of 
BRISC-SHMT2 interfaces. Residues labeled in red were mutated in validation analysis.  
 
Figure 3. BRISC-SHMT2 interaction is important for interferon signaling 
a & b) Immunoprecipitation (IP) was performed using anti-Flag antibody in 293T cells transiently 
transfected with Flag-HA epitope-tagged Abraxas2 wild-type (WT) or mutants. Immunoblotting was 
performed for the indicated proteins.  
c) Abraxas2–/– MEFs and Abraxas2–/– MEFs stably reconstituted with WT or mutants were infected 
with Herpes Simplex Virus (HSV) lacking the lytic phase gene ICP0. IFN signalling was assessed 
by immunoblotting for STAT1 phosphorylated at Y701 (pSTAT1). 
d) WT MEFs overexpressing Abraxas2 WT or E144R were challenged with LPS and IFNb. IFN 
signaling was assessed as in c. Data in a-d are representative of three independent experiments. 
For gel source data, see Supplementary Figure 1. 
e) Volcano plots illustrating the fold change in gene expression of IFN type I-stimulated genes 
relative to Abraxas2–/– KO MEFs without LPS treatment. p-values were calculated using a 
Student’s t-test (two-tail distribution and equal variances between the two samples) on the triplicate 
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2^(-DCT) values for each gene in each treatment group compared to the control group. Genes 
below the p=0.05 threshold were upregulated in WT+LPS, but represented as below statistical 
significance due to the relative expression in KO samples being almost zero. Regulated genes are 
highlighted in Extended Data Fig. 9a.  
 
Figure 4. PLP regulation of BRISC-SHMT2 interaction and signaling 
a) Immunoprecipitation (IP) of stably expressed Flag-HA epitope-tagged SHMT2DN using an anti-Flag 
antibody. Immunoblotting was performed after pyridoxal (PL) treatment for 48 h. b) GC-MS 
measurements of B6 vitamers from whole cell lysates after culturing for 48 h in B6 vitamer-free media 
with and without PL. PLP = pyridoxal-5’-phosphate; PN = pyridoxine. c) IP of ectopically expressed 
Abraxas2 using an anti-Flag antibody in MEFs grown in B6 vitamer-free media for 48 h. Immunoblotting 
was performed for the indicated proteins after 20 µM PL addition and/or 500 units/mL mouse IFNb. d) 
IP using an anti-Flag antibody in MEFs stably expressing Flag-HA epitope-tagged SHMT2 forms. 
Immunoblotting was performed after treatment with 20 µM PL for 48 h. e) pSTAT1 levels in MEFs 
stably expressing SHMT2 forms and cultured in B6 vitamer-free media. Cells were treated with 20 µM 
PL and/or 500units/ml IFNb for 48h. Data in a, c-e are representative of three independent experiments. 
For gel source data, see Supplementary Figure 1. f) Volcano plots comparing type I IFN-induced gene 
expression in MEFs stimulated with LPS and cultured in the absence (PL–) or presence (PL+) of 20 µM 
PL. p-values were calculated using a Student’s t-test (two-tail distribution and equal variances between 
the two samples) on the triplicate 2^(-DCT) values for each gene in each treatment group compared to 
the control group. 
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Extended Data Figure Legends 
 
Extended Data Figure 1. SHMT2 exists in a dimer-tetramer equilibrium 
a) Structure of SHMT2!N+A285T dimer (PDBid 6DK3). Unbiased electron density maps are coloured 
green. The structure was erroneously deposited by the Structural Genomics Consortium (SGC) as wild 
type with PDBid 3OU5. It was corrected and redeposited with PDBid 6DK3 on 28 May 2018. b) 
Structure of wild type (WT) SHMT2α tetramer (PDBid 4PVF) bound to pyridoxal-5’-phosphate (PLP). 
Regions in red show structural rearrangements upon PLP binding. c) Native mass spectrometry spectra 
(single measurement experiment) of SHMT2!N forms (top) and measured and calculated masses 
(bottom). Calculated masses nearest to the measured masses are underlined. d) Size exclusion 
chromatography profiles of SHMT2!N forms (top) and a Coomassie-stained SDS-PAGE gel (bottom). 
Data are representative of three independent experiments. e) Comparison of SHMT2 protomers with 
and without PLP. 
 
Extended Data Figure 2. PLP regulates SHMT2 dimer-tetramer transition 
a) PLP association to the indicated SHMT2ΔN forms. SHMT2-PLP internal aldimine linkage was 
monitored by measuring absorbance at 435 nm after rapid mixing of SHMT2ΔN (5 µM) and PLP (100 
µM). Data are average +/- SEM of four independent reactions. 
b) Enzyme activity of the indicated SHMT2ΔN forms (0.5 µM) against the synthetic substrate L-threo-
phenylserine in the presence of 50 µM PLP. Reaction was monitored by measuring benzyldehyde 
absorbance at 279 nm. Data are average +/- SEM of three independent experiments carried out in 
duplicate. 
c) Differential scanning fluorimetry (DSF) analysis of SHMT2ΔN forms in the presence and absence of 
PLP. SHMT2ΔN WT and mutant proteins (5 µM) were incubated with the indicated concentrations of 
PLP or 100 µM 2-Hydroxy-6-methylpyridine-3-carboxylic acid (HMCA) for 10 min at 20 oC prior to DSF 
analysis.     
d) Changes in melting temperatures (ΔTm) for each of the conditions shown in c. ΔTm was calculated 
by subtracting the Tm of SHMT2 with buffer without ligands from the Tm of SHMT2 with added ligands. 
Data in c, d represent a single experiment carried out in duplicate. 
e) Summary of SHMT2ΔN+A285T dimer-tetramer equilibrium in response to PLP binding. 
 
Extended Data Figure 3. Reconstitution of BRISC-SHMT2 complex  
a) Summary of limited proteolysis and Edman sequencing results indicating trypsin protease-labile 
regions for the BRCC45-MERIT40 complex (left) and the BRISC complex (right). Protease cleavage 
sites are shown as scissors. Unstructured Abraxas2 regions are indicated as dashed lines. MPN = 
Mpr1/Pad1 N-terminal, CC = coiled coil, UEV = Ubiquitin E2 variant, vWFA = von Willebrand factor type 
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A. b) SDS-PAGE of BRISC and BRISCΔNΔC complexes (representative of three independent 
experiments). c) DUB activity of BRISC (full length) and BRISCΔNΔC (truncated) complexes against a 
fluorogenic K63-linked diUb substrate. Data are average +/-SEM of three independent experiments 
carried out in duplicate. d) SHMT2ΔN+A285T inhibition of BRISC and BRISCΔNΔC DUB activity. Data 
are average +/-SEM of three independent experiments carried out in duplicate. 95% confidence 
intervals are shown in square brackets. e) Size exclusion chromatography of the BRISCΔNΔC-
SHMT2ΔN+A285T complex (top) and Coomassie-stained SDS-PAGE of peak fractions (bottom). f) 
Native mass spectrometry of the BRISCΔNΔC-SHMT2ΔN+A285T complex. Data in e, f are 
representative of three independent experiments. 
 
Extended Data Figure 4. Electron microscopy (EM) analysis of  BRISC and  BRISC-SHMT2 
complexes  
a) Negative stain EM analysis. Selected 2D averaged classes of BRISCΔNΔC (left) and BRISCΔNΔC-
SHMT2ΔN+A285T (right). 
b) Representative cryo-EM micrograph. Green circles (180 Å diameter) indicate auto-picked particles. 
c) Flowchart of data processing. Final electron microscopy maps colored according to local resolution 
are provided (scale bar in Å). d) Fourier Shell Correlation (FSC) curves for the indicated maps. The final 
resolution was calculated using the “gold-standard” FSC cut-off at 0.143 frequency.  
 
Extended Data Figure 5. Structural analysis of BRISC-SHMT2 structures 
a) Structural overview of the BRISCΔNΔC-SHMT2 structure and cryo-EM maps at a contour level of 
0.085 (C2 map), showing secondary structure features. BRCC45 UEV-C and MERIT40 vWFA domains 
were omitted. CCHB = coiled coil helical bundle. Asterisks mark the position of BRCC36 active site. An 
overreaching loop (SHMT2 residues 296-307) is coloured red. b) Representative EM map of BRCC36 
active site. c & d) Superdimer BRCC36-Abraxas2 structures of human (c) and insect (C. floridanus) (d) 
highlighting differences and similarities. Connectivity of the MPN– domain of Abraxas2 and helix α4 by a 
crossover loop is different in the human complex and is colored orange. e) Superimposition of the 
BRCC36 MPN+ domain from the insect (gray) and human (blue, green) heterodimers. Abraxas2 regions 
with notable differences between the two structures are colored orange.  
  
Extended Data Figure 6. Analysis of SHMT1 interaction with BRISC 
a) Elution profile of WT-SHMT1 from an S75 16/600 size exclusion chromatography column (data are 
representative of two independent experiments).  
b) Elution profile of SHMT1 containing mutated residues designed to break the tetrameric interface (left 
panel; data are from a single experiment). Structure of SHMT1 tetramer (PDBid 1RV4) highlighting 
residues important for tetramerization (right panel).   
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c) BRISC DUB activity against a fluorogenic K63-linked diUb substrate in the presence of the indicated 
SHMT1 and SHMT2 forms. Data are average +/-SEM of three independent experiments carried out in 
duplicate. For gel source data, see Supplementary Figure 1. 
d) Coomassie-stained SDS-PAGE analysis of the indicated SHMT1 and SHMT2 protein preparations 
(data are from a single experiment).  
e) Analytical size exclusion chromatography runs of the indicated protein preparations. SHMT1 proteins 
were mixed with BRISC for 30 min before injecting on a 2.4 ml Superose 6 column (bottom traces). 
Traces on top are control runs. A BRISC-SHMT2ΔN run is shown as reference (see Extended Fig. 8e 
for detailed analysis).  
f) Coomassie-stained SDS-PAGE analysis of the indicated peak fractions from size exclusion runs 
shown in panel e. Data in e, f are from a single experiment.   
  
Extended Data Figure 7. Purification and analysis of SHMT2 mutants 
a) Elution profile of the indicated SHMT2ΔN forms from an S75 10/300 size exclusion chromatography 
column (single experiment). b) Coomassie-stained SDS-PAGE analysis of the indicated SHMT2ΔN 
protein preparations (data are representative of two independent experiments). c) BRISC DUB activity 
against a fluorogenic K63-linked diUb substrate in the presence of the indicated SHMT2ΔN mutants. 
Data are average +/-SEM of three independent experiments carried out in duplicate.  d) BRISC DUB 
activity against K63-linked hexa-Ub chains in the presence of the SHMT2ΔN or SHMT1 forms. e) 
Ubiquitylation levels of IFNAR1 after IFNa stimulation in 293T cells overexpressing the indicated 
Abraxas2 and SHMT2ΔN forms (LL->RR = L211R+L215R). IFNAR1 immunoprecipitation (IP) was 
performed under denaturing conditions and ubiquitin levels were detected using the vu-1 antibody. 
Mock IP was performed using a generic rabbit IgG antibody. f) Immunoprecipitation (IP) performed 
using anti-Flag antibody in MEFs transiently transfected with Flag-HA epitope-tagged SHMT2ΔN or 
mutants. Immunoblot was performed for Abraxas2 and SHMT2 as indicated. UTF = untransfected cells 
used as control. g) MEFs overexpressing the indicated SHMT2ΔN or mutants were challenged with 
LPS and interferon receptor-dependent signal transduction response was assessed by immunoblot for 
STAT1 phosphorylated at Y701 (pSTAT1). Data shown in d-e are representative of three independent 
experiments. For gel source data, see Supplementary Figure 1. 
 
Extended Data Figure 8. SHMT2 blocks the BRISC active site 
a) Analytical size exclusion chromatography (SEC) of SHMT2ΔN forms preincubated with BRISC (left) 
and SDS-PAGE analysis of peak fractions (right). Data are from a single experiment. b) K63-linked 
diUb (gray) modeled on the MPN+ domain of BRCC36 using the AMSH-LP–diUb structure (PDBid 
2ZNV) as a guide. SHMT2 obligate dimer sterically clashes with the modeled proximal ubiquitin. c) 
Michaelis-Menten (top) and Lineweaver-Burk (bottom) plots for BRISC DUB activity against a K63-diUb 
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fluorogenic substrate with addition of SHMT2ΔN+A285T. Technical duplicates are shown and data are 
representative of two independent experiments. d) Superimposition of SHMT2 dimer and tetramer 
forms. SHMT2 obligate dimer from the PLP-bound tetramer structure (PDBid 4PVF, colored gray) was 
overlaid to the SHMT2ΔN+A285T dimer bound to BRISC. The second obligate dimer from the SHMT2-
PLP holoenzyme sterically clashes with the BRCC36-Abraxas2 superdimer. Movement of helices α6 
and α7 is indicated. e) Analytical SEC of SHMT2ΔN dimer and tetramer (+PLP) forms with BRISC (left) 
and SDS-PAGE analysis of peak fractions (right). Data are from a single experiment. 
 
Extended Data Figure 9. Regulation of BRISC-SHMT2 function in cells 
a) Schematic of pairwise comparison of Abraxas2–/– MEFs treated with LPS and expressing the 
indicated Abraxas2 forms (top panel). Bar chart illustrates the IFN type I-related genes that were >2 fold 
increased in Abraxas2 WT+LPS (black) and Abraxas2 E144R+LPS (blue) relative to KO+LPS. Data are 
presented as mean +/- SEM from three independent experiments (biological replicates). 
b) Native gel electrophoresis of whole MEF cell lysates cultured in B6 vitamer-free media with and 
without pyridoxal (PL) and expressing the indicated Flag-HA-SHMT2ΔN forms. 
c & d) Measurement of pSTAT1 levels (pY701) in MEFs (c) or MEFs stably expressing SHMT2 (d) and 
cultured in B6 vitamer-free media. Where indicated, cells were treated with 20 µM PL and/or or 500 
units/mL IFNb for 48 h. 
e) IP performed using anti-Flag antibody in MEFs transiently transfected with Flag-HA epitope-tagged 
SHMT2 or mutants (cultured in DMEM). Immunoblot was performed for Abraxas2 and SHMT2 as 
indicated.  
f) pSTAT1 levels (pY701) measured in MEFs cultured in DMEM containing B6 and the indicated 
SHMT2 forms after challenging with HSV. Data shown in b-f are representative of three independent 
experiments. For gel source data, see Supplementary Figure 1. 
 
Extended Data Figure 10. Proposed model of BRISC-SHMT2 regulation of cytokine signaling 
K63-linked poly-ubiquitylated interferon receptors (IFNAR1/2) are internalized and degraded via the 
lysosomal degradation pathway. The BRISC-SHMT2 complex is required for IFNAR1/2 deubiquitylation 
and receptor stabilization at the membrane. BRISC deubiquitylation of IFNAR1/2 receptors proceeds 
after SHMT2 displacement leading to sustained interferon signaling. 
 
SHMT2 dimer-tetramer transition is regulated by pyridoxal-5’-phosphate (PLP) binding. Only an inactive 
SHMT2 dimer can interact with BRISC, whereas the active SHMT2 tetramer will sterically clash with 
BRCC36-Abraxas2 superdimer. Modulation of SHMT2 dimer-tetramer transition by PLP analogues or 
other binders could represent new ways to inhibit BRISC recruitment to IFNAR1/2 and reduction of 
interferon signaling. 
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Extended Data Table 1. Summary of data collection, image processing, model building, refinement 
and validation statistics.  
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 BRISCDNDC-SHMT2 
EMD-4759/EMD-4760, PDB 6R8F 
BRISCDNDC-
SHMT2 
BRISCDNDC 
Staining None Uranyl acetate Uranyl acetate 
Data Collection    
Microscope FEI Titian KRIOS FEI Tecnai F20 FEI Tecnai F20 
Voltage (keV) 300 120 120 
Detector FEI Falcon III FEI Ceta CMOS  FEI Ceta CMOS 
Magnification x75,000  x29,000 x29,000 
Defocus range (µm) -1.6 to -3.1   
Pixel size (Å)  1.065 3.51 3.51 
Electron dose (e–/Å2) 
Dataset 1: 95 
Dataset 2: 83 
Dataset 3: 86 
15 15 
Electron dose per frame (e-/Å2) 1.2   
Exposure (sec) 2 1.5 1.5 
No. of frames 
Dataset 1: 79 
Dataset 2: 70 
Dataset 3: 71 
1 1 
No. of micrographs 7,494 222 218 
Data Processing 
Complete 
dataset 
2-arm dataset   
  Symmetry Point Group C1 C2   
  Final particle number 403,499 64,403   
Map resolution (Å) 3.8 4.2   
      FSC threshold 0.143 0.143   
Map resolution range (Å) 3.5 – 10.0 3.9 – 11.5   
Refinement     
Initial models used (PDB code) 5CW3, 6DK3 5CW3, 6DK3   
Map sharpening B-factor (Å2) -202 -182   
Model Composition     
      Non-hydrogen atoms 15,810 15,810   
      Protein residues 2,164 2,164   
      Zinc ions 2 2   
R.M.S.D from ideal geometry      
       Bonds lengths (Å)  0.01 0.01   
       Bond angles (o)  1.07 1.00   
Validation     
      Molprobity score  
1.72 
(88th percentile) 
1.80 
(85th percentile) 
  
      Clashscore 
3.53 
(97th percentile) 
4.53 
(95th percentile) 
  
    Poor rotamers (%) 0.00 0.27   
Ramachandran plot statistics     
    Favored (%) 89.08 89.32   
      Allowed (%) 10.92 10.68   
      Disallowed (%) 0.00 0.00   
 
